预约演示
更新于：2026-05-28
Entacapone
恩他卡朋
更新于：2026-05-28
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (1998-09-16), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C14H15N3O5 |
InChIKeyJRURYQJSLYLRLN-BJMVGYQFSA-N |
CAS号130929-57-6 |
关联
41
项与 恩他卡朋 相关的临床试验TCTR20250905008
A Single Dose, Randomized, Open-label, Four-period, Replicate Crossover Bioequivalence Study of Generic Entacapone 200 mg Film-coated Tablets and Reference Product (Comtan) in Healthy Thai Volunteers under Fasting Conditions
CTR20253873
恩他卡朋片在中国健康研究参与者中空腹和餐后状态下随机、开放、单剂量、两序列、四周期、重复交叉生物等效性研究
ChiCTR2500104562
Exploratory Clinical Study ofEntacapone Combined with PD-1/1Antibody andTargeted Therapy in Advanced Hepatocellular Carcinoma Refractory to StandardTreatment
100 项与 恩他卡朋 相关的临床结果
登录后查看更多信息
100 项与 恩他卡朋 相关的转化医学
登录后查看更多信息
100 项与 恩他卡朋 相关的专利（医药）
登录后查看更多信息
1,015
项与 恩他卡朋 相关的文献（医药）2026-06-01Drug Metabolism and Pharmacokinetics
N6-methyladenosine modification of MRP7 mRNA modulates its expression and paclitaxel sensitivity in lung cancer-derived A549 cells
Article
作者: Nakajima, Miki ; Inamoto, Takuto ; Fukami, Tatsuki ; Nakano, Masataka
Methylation of adenosine at the N6 position (m6A modification) is the most prevalent epitranscriptomic modification in mammals, regulating RNA stability, splicing, translation, and decay. Growing evidence has revealed that m6A modification is intricately linked to cancer progression. This study aimed to investigate the effects of m6A modification on the sensitivity of lung cancer-derived A549 cells to paclitaxel (PTX). Knockdown of methyltransferase like (METTL) 3/14, the m6A writer complex, increased A549 cell viability under PTX, indicating m6A modification enhances PTX sensitivity. METTL3/14 knockdown increased the expression of multidrug resistance-associated protein (MRP) 7, but not multiple drug resistance (MDR) 1 or MRP1, promoting PTX efflux. RNA immunoprecipitation showed that MRP7 mRNA is highly methylated at the 5'-untranslated region (UTR), coding region, and 3'-UTR. METTL3/14 knockdown stabilized MRP7 mRNA, while depletion of m6A readers YTHDC2 or YTHDF2 also elevated MRP7 mRNA, suggesting these readers mediate its degradation. Moreover, knockdown of the erasers fat mass and obesity-associated protein (FTO) or AlkB homolog 5 as well as treatment with entacapone, an FTO inhibitor, increased PTX sensitivity in PTX-resistant A549 cells. These results suggest that the m6A-dependent regulation of MRP7 expression contributes to PTX resistance, highlighting a potential therapeutic avenue in lung cancer.
2026-06-01BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
The Cardiovascular Safety of Antiparkinsonian Drugs—Analysis of Signals in the FDA Adverse Event Report System Database
Article
作者: Mu, Xin ; Ning, Pingping ; Wang, Yanfeng ; Wei, Peiyao ; Ren, Junwei
ABSTRACT:
Objective:
This study aimed to investigate the characteristics and spectrum of cardiotoxicity induced by various antiparkinsonian drugs based on the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.
Methods:
Data from the FAERS database from the first quarter of 2004 to the third quarter of 2025 were downloaded for disproportionality analysis. We employed validated disproportionality metrics including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN) and multi‐item gamma Poisson shrinker (MGPS) to detect significant drug‐event associations.
Results:
After removing duplicates, a total of 42 583 cases of patients treated with antiparkinsonian drugs were included in the FAERS database. Dopamine receptor agonists exhibited the most extensive range of cardiac adverse events. Monoamine oxidase B inhibitors displayed the second broadest range of toxicity. As for catechol‐O‐methyltransferase inhibitors, a total of six signals were detected in entacapone. Four signals were detected for amantadine, while no signals were identified for levodopa.
Conclusion:
This study highlights the cardiovascular adverse reactions associated with Parkinson's treatment drugs. These findings underscore the importance of monitoring and evaluating the cardiovascular safety of antiparkinsonian medications.
2026-05-01JOURNAL OF NEUROLOGY
Patient-reported outcomes and experiences with COMT inhibitors in the management of motor fluctuations in Parkinson’s disease: a UK-based nested cross-sectional study
Article
作者: Noyce, Alastair J ; Maio, Raquel ; Periñan, Maria Teresa ; Efthymiadou, Olina ; Harrison-Jones, Glynn ; Akindele, Lara ; Ippolito, Mario ; Shelton, Emma-Louise
BACKGROUND:
Motor fluctuations are a common complication in Parkinson's disease (PD), often managed with catechol-O-methyltransferase (COMT) inhibitors. We aimed to explore patient perspectives on their COMT inhibitor treatment and to evaluate and compare patient-reported outcomes and experiences with the COMT inhibitors opicapone and entacapone.
METHODS:
This UK-based cross-sectional study utilised anonymised, real-world data from the AccessPD registry. A convenience sample of 102 registry participants who had received either opicapone or entacapone. completed validated patient-reported outcome measures (PDQ-39 and, EQ-5D-5L) and an online survey assessing treatment experiences, preferences, and communication with healthcare providers.
RESULTS:
Survey responses highlighted that increased ON time and reduced OFF time were the most valued treatment attributes for COMT inhibitors, while hallucinations and dyskinesia were the least acceptable side effects. Only 25% of respondents recalled being informed about alternative treatment options prior to starting COMT inhibitor therapy. Communication from clinicians about the role of these drugs was inconsistent, with 27.5% of participants only rating it as 'fair/poor' and 58% reporting no follow-up after initiation. Patients' overall quality of life was generally reported as mild to moderately affected in both treatment groups.
CONCLUSIONS:
Survey findings underscore the heterogeneity of patient preferences and the need for improved clinician-patient communication and personalised care. Both COMT inhibitors should be considered in shared decision-making to optimise motor fluctuation management and quality of life in PD.
100 项与 恩他卡朋 相关的药物交易
登录后查看更多信息
研发状态
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 551 | 築繭衊範蓋製構糧壓齋(鏇獵襯衊夢鬱鏇襯淵積) = 積觸廠淵鏇製鏇鏇糧簾 糧製齋繭窪齋齋齋觸選 (艱積製衊顧願襯構醖鏇 ) 更多 | - | 2015-12-01 | ||
築繭衊範蓋製構糧壓齋(鏇獵襯衊夢鬱鏇襯淵積) = 構蓋選範遞遞窪憲鏇壓 糧製齋繭窪齋齋齋觸選 (艱積製衊顧願襯構醖鏇 ) 更多 | |||||||
临床1/2期 | 14 | (LDOPS + Placebo; LDOPS + CAR; LDOPS + ENT) | 膚糧鹹繭艱夢膚淵廠壓(窪膚範積夢顧構鹽鑰鏇) = 鹹鏇積簾膚窪夢範齋蓋 淵觸夢壓製餘觸鹹膚遞 (構鹽醖遞繭簾願齋構膚, 餘構範膚簾構築餘鹽淵 ~ 窪願蓋艱獵選繭築築憲) 更多 | - | 2014-07-17 | ||
(LDOPS + Placebo; LDOPS + Ent; LDOPS + CAR) | 膚糧鹹繭艱夢膚淵廠壓(窪膚範積夢顧構鹽鑰鏇) = 繭築衊鏇築網構顧憲選 淵觸夢壓製餘觸鹹膚遞 (構鹽醖遞繭簾願齋構膚, 糧醖淵醖觸製憲選鏇鏇 ~ 艱膚選築鹽網糧壓繭鏇) 更多 | ||||||
N/A | - | Immediate Switch to Levodopa/Carbidopa/Entacapone | 範餘製壓鹽淵襯觸淵鑰(願艱窪齋壓襯鹽鑰餘繭) = 築糧製淵鑰艱糧範顧築 齋壓築餘齋醖製積觸鑰 (鏇糧憲獵製鹹醖壓鹽餘 ) 更多 | 积极 | 2011-10-13 | ||
Delayed Switch to Levodopa/Carbidopa/Entacapone | 範餘製壓鹽淵襯觸淵鑰(願艱窪齋壓襯鹽鑰餘繭) = 憲願遞積淵選鏇積選製 齋壓築餘齋醖製積觸鑰 (鏇糧憲獵製鹹醖壓鹽餘 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用